Search results for " ratio"

showing 10 items of 3859 documents

Seafood Consumption, Omega-3 Fatty Acids Intake, and Life-Time Prevalence of Depression in the PREDIMED-Plus Trial.

2018

Background: The aim of this analysis was to ascertain the type of relationship between fish and seafood consumption, omega-3 polyunsaturated fatty acids (&omega

0301 basic medicineMaleeicosapentaenoic acidmodelos logísticoshumanosdepresiónencuestas sobre dietas0302 clinical medicineClinical trialsSurveys and QuestionnairesOdds RatioPrevalence030212 general & internal medicineDepressió psíquicamediana edadDietoteràpia2. Zero hungerancianoNutrition and Dieteticsintegumentary systemdietaDepressionEuropean researchFatty AcidsprevalenciaFishesfood and beveragesMiddle Ageddocosahexaenoic acidcociente de probabilidades relativasMental depressiondepressionChristian ministryFemaleomega-3lcsh:Nutrition. Foods and food supplyEuropean Regional Development Fundlcsh:TX341-641Àcids grassos omega-3Diet SurveysArticle03 medical and health sciencesalimentos del marDepression (economics)pecestrastorno depresivoEnvironmental healthPolitical scienceFatty Acids Omega-3ingesta energéticaOmega-3 fatty acidsAnimalsHumansácidos grasosAgedConsumption (economics)fishconducta alimentariaDepressive Disorder030109 nutrition & dieteticsDiet therapyLife timeFeeding BehaviorPredimedDietCross-Sectional StudiesLogistic ModelsSeafoodanimalesEnergy IntakeFood Scienceestudios transversalesAssaigs clínicsNutrients
researchProduct

Prenatal exposure to endocrine disrupting chemicals and risk of being born small for gestational age: Pooled analysis of seven European birth cohorts

2018

Background and aims: There is evidence that endocrine disrupting chemicals (EDCs) have developmental effects at environmental concentrations. We investigated whether some EDCs are associated with the adverse birth outcome Small for Gestational Age (SGA). Methods: We used PCB 153, p,p'-DDE, HCB, PFOS and PFOA measured in maternal, cord blood or breast milk samples of 5446 mother-child pairs (subset of 693 for the perfluorinated compounds) from seven European birth cohorts (1997–2012). SGA infants were those with birth weight below the 10th percentile for the norms defined by gestational age, country and infant's sex. We modelled the association between measured or estimated cord serum EDC co…

0301 basic medicineMalemedicine.medical_specialtyBirth weight010501 environmental sciencesBreast milkEndocrine Disruptors01 natural sciencesPooled analysis03 medical and health sciencesSDG 3 - Good Health and Well-beingInterquartile rangePregnancyMedicine[SDV.EE.SANT] Life Sciences [q-bio]/Ecology environment/HealthHumansBiologylcsh:Environmental sciences0105 earth and related environmental sciencesGeneral Environmental Science2. Zero hungerlcsh:GE1-350[SDV.EE.SANT]Life Sciences [q-bio]/Ecology environment/HealthPregnancyMilk Humanbusiness.industryObstetricsSmokingInfant NewbornGestational ageEnvironmental exposureOdds ratioEndocrine disrupting chemicals (EDCs)Infant Low Birth Weightmedicine.diseaseFetal Blood3. Good healthChemistrySmall for gestational age (SGA)030104 developmental biology[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieMaternal ExposurePrenatal Exposure Delayed EffectsSmall for gestational age/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemale[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusiness
researchProduct

Elevated Fatty Liver Index as a Risk Factor for All‐Cause Mortality in Human Immunodeficiency Virus–Hepatitis C Virus–Coinfected Patients (ANRS CO13 …

2020

International audience; Background and aims: Human immunodeficiency virus (HIV)-hepatitis C virus (HCV)-coinfected patients are at high risk of metabolic complications and liver-related events, which are both associated with hepatic steatosis and its progressive form, nonalcoholic steatohepatitis, a known risk factor for mortality. The fatty liver index (FLI), a noninvasive steatosis biomarker, has recently drawn attention for its clinical prognostic value, although its capacity to predict mortality risk in HIV-HCV-coinfected patients has never been investigated. Using a Cox proportional hazards model for mortality from all causes, with data from the French National Agency for Research on A…

0301 basic medicineMalemedicine.medical_specialtyCirrhosisHepatitis C virusmedicine.medical_treatment[SDV]Life Sciences [q-bio]HIV InfectionsLiver transplantationmedicine.disease_causeGastroenterologyAntiviral AgentsCohort Studies03 medical and health sciences0302 clinical medicineRisk Factors[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesInternal medicineCause of DeathmedicineHumansRisk factorComputingMilieux_MISCELLANEOUSHepatologybusiness.industryCoinfectionHazard ratioFatty liverHepatitis C ChronicMiddle Agedmedicine.disease3. Good healthFatty Liver[SDV] Life Sciences [q-bio]030104 developmental biology[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases030211 gastroenterology & hepatologyFemaleFranceSteatosisViral hepatitisbusiness
researchProduct

Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis.

2018

ObjectiveHomozygous alpha1-antitrypsin (AAT) deficiency increases the risk for developing cirrhosis, whereas the relevance of heterozygous carriage remains unclear. Hence, we evaluated the impact of the two most relevant AAT variants (‘Pi*Z’ and ‘Pi*S’), present in up to 10% of Caucasians, on subjects with non-alcoholic fatty liver disease (NAFLD) or alcohol misuse.DesignWe analysed multicentric case–control cohorts consisting of 1184 people with biopsy-proven NAFLD and of 2462 people with chronic alcohol misuse, both cohorts comprising cases with cirrhosis and controls without cirrhosis. Genotyping for the Pi*Z and Pi*S variants was performed.ResultsThe Pi*Z variant presented in 13.8% of p…

0301 basic medicineMalemedicine.medical_specialtyHeterozygoteCirrhosisMedizinSingle-nucleotide polymorphismDiseaseGastroenterologyPolymorphism Single NucleotideRisk Assessment03 medical and health sciences0302 clinical medicineAge DistributionLiver Cirrhosis AlcoholicNon-alcoholic Fatty Liver DiseaseInternal medicineGermanymedicinePiConfidence IntervalsOdds RatioHumansGenetic Predisposition to DiseaseRisk factorSex DistributionGenotypingLiver injurybusiness.industryGenetic Carrier ScreeningIncidenceFatty liverBiopsy NeedleGastroenterologyGenetic Variationmedicine.diseasePrognosisImmunohistochemistry030104 developmental biologyAustriaCase-Control Studiesalpha 1-Antitrypsin030211 gastroenterology & hepatologyFemalebusinessGut
researchProduct

Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real‐life setting: the PROSISA Study

2021

Aim: Statin-associated muscle symptoms (SAMS) are a major determinant of poor treatment adherence and/or discontinuation, but a definitive diagnosis of SAMS is challenging. The PROSISA study was an observational retrospective study aimed to assess the prevalence of reported SAMS in a cohort of dyslipidaemic patients. Methods: Demographic/anamnestic data, biochemical values and occurrence of SAMS were collected by 23 Italian Lipid Clinics. Adjusted logistic regression was performed to estimate odds ratio (OR) and 95% confidence intervals for association between probability of reporting SAMS and several factors. Results: Analyses were carried out on 16 717 statin-treated patients (mean ± SD, …

0301 basic medicineMalemedicine.medical_specialtySettore MED/09 - Medicina Internaadverse effects; myopathy; statin-associated muscle symptoms; statinsstatin-associated muscle symptomsadverse effects; myopathy; statin-associated muscle symptoms; statins.030204 cardiovascular system & hematologystatinsMedication Adherence03 medical and health sciences0302 clinical medicineMuscular DiseasesInternal medicineadverse effectInternal MedicinemedicinePrevalencestatins.Humansstatin‐associated muscle symptomsAdverse effectDechallengeadverse effects; myopathy; statin-associated muscle symptoms; statins; Creatine Kinase; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Italy; Male; Medication Adherence; Middle Aged; Muscular Diseases; Prevalence; Retrospective StudiesCreatine KinaseDyslipidemiasRetrospective Studiesbusiness.industryRetrospective cohort studyOdds ratioOriginal ArticlesMiddle AgedConfidence intervalDiscontinuation030104 developmental biologyItalyConcomitantCohortadverse effectsOriginal ArticleFemaleHydroxymethylglutaryl-CoA Reductase Inhibitorsbusinessstatin-associated muscle symptommyopathyJournal of Internal Medicine
researchProduct

Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Dif…

2018

AbstractAimsRelatively little is known about the health outcomes associated with very low plasma concentrations of high-density lipoprotein cholesterol (HDL-C) mainly because of the small numbers of individuals with such extreme values included in clinical trials. We, therefore, investigated the association between low and very low HDL-C concentration at baseline and incident all-cause-mortality, death from malignant disease (i.e. cancer), and with fatal or non-fatal incident coronary heart disease (CHD) in individuals from the Reasons for Geographical And Racial Differences in Stroke (REGARDS) study.Methods and resultsAnalysis was based on 21 751 participants from the REGARDS study who wer…

0301 basic medicineMalemedicine.medical_specialtyTime FactorsPhysiologyDown-RegulationCoronary Disease030204 cardiovascular system & hematologyRisk AssessmentWhite People03 medical and health sciences0302 clinical medicineSex FactorsRisk FactorsPhysiology (medical)Internal medicineCause of DeathNeoplasmsmedicineHumansLongitudinal StudiesStrokeCause of deathAgedDyslipidemiasCancer Death Ratebusiness.industryProportional hazards modelIncidence (epidemiology)IncidenceHazard ratioCholesterol HDLHealth Status DisparitiesMiddle AgedProtective Factorsmedicine.diseaseConfidence intervalUnited StatesResidual riskBlack or African AmericanStroke030104 developmental biologyFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersCardiovascular research
researchProduct

Intravenous thrombolysis for suspected ischemic stroke with seizure at onset

2019

Objective Seizure at onset (SaO) has been considered a relative contraindication for intravenous thrombolysis (IVT) in patients with acute ischemic stroke, although this appraisal is not evidence based. Here, we investigated the prognostic significance of SaO in patients treated with IVT for suspected ischemic stroke. Methods In this multicenter, IVT-registry-based study we assessed the association between SaO and symptomatic intracranial hemorrhage (sICH, European Cooperative Acute Stroke Study II definition), 3-month mortality, and 3-month functional outcome on the modified Rankin Scale (mRS) using unadjusted and adjusted logistic regression, coarsened exact matching, and inverse probabil…

0301 basic medicineMalemedicine.medical_specialtymedicine.medical_treatmentLogistic regressionGUIDELINESCLASSIFICATION3124 Neurology and psychiatryBrain IschemiaEARLY MANAGEMENT03 medical and health sciences0302 clinical medicineALTEPLASEModified Rankin ScaleSeizuresMIMICSInternal medicineMedicineHumansThrombolytic TherapyPLASMINOGEN-ACTIVATOR610 Medicine & healthStrokeContraindicationPOPULATIONAgedAged 80 and overHEALTH-CARE PROFESSIONALSbusiness.industryConfounding3112 NeurosciencesOdds ratioThrombolysisASSOCIATIONMiddle Agedmedicine.diseasePrognosisConfidence intervalStroke030104 developmental biologyTreatment OutcomeNeurologySAFETYFemaleNeurology (clinical)business030217 neurology & neurosurgery
researchProduct

Clinical effectiveness of influenza vaccination after allogeneic hematopoietic stem cell transplantation: A cross-sectional prospective observational…

2018

Abstract Background Vaccination is the primary method for preventing influenza respiratory virus infection (RVI). Although the influenza vaccine is able to achieve serological responses in some allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients, its clinical benefits are still uncertain. Methods In this prospective, cross-sectional study, we retrospectively analyzed the effect of inactivated trivalent influenza vaccination on the prevalence of influenza RVI in a consecutive cohort of 136 allo-HSCT adult recipients who developed 161 RVI over 5 flu seasons (from 2013 to 2018). Respiratory viruses in upper– and/or lower–respiratory tract specimens were tested using multi…

0301 basic medicineMalemedicine.medical_treatmentHematopoietic stem cell transplantationinfluenza virus0302 clinical medicineRisk FactorsOdds RatioMedicine030212 general & internal medicineProspective StudiesArticles and CommentariesImmunodeficiencybiologyVaccinationHematopoietic Stem Cell Transplantationvirus diseasesMiddle AgedVaccinationHospitalizationInfectious DiseasesTreatment OutcomeInfluenza VaccinesCohortFemaleMicrobiology (medical)Adultmedicine.medical_specialtyAdolescentInfluenza vaccine030106 microbiologyOrthomyxoviridae03 medical and health sciencesImmunocompromised HostYoung AdultInternal medicineInfluenza HumanHumansTransplantation Homologousallogeneic hematopoietic stem cell transplantationRisk factorAgedRetrospective Studiescommunity-acquired respiratory virusbusiness.industryOdds ratiomedicine.diseasebiology.organism_classificationCross-Sectional StudiesSpainbusinessimmunodeficiency score index
researchProduct

Polyphenol Levels Are Inversely Correlated with Body Weight and Obesity in an Elderly Population after 5 Years of Follow Up (The Randomised PREDIMED …

2017

Overweight and obesity have been steadily increasing in recent years and currently represent a serious threat to public health. Few human studies have investigated the relationship between polyphenol intake and body weight. Our aim was to assess the relationship between urinary polyphenol levels and body weight. A cross-sectional study was performed with 573 participants from the PREDIMED (Prevención con Dieta Mediterránea) trial (ISRCTN35739639). Total polyphenol levels were measured by a reliable biomarker, total urinary polyphenol excretion (TPE), determined by the Folin-Ciocalteu method in urine samples. Participants were categorized into five groups according to their TPE at the fifth …

0301 basic medicineMaleobesityCross-sectional studyUrineOverweightBody Mass IndexSurveys and QuestionnairesPrevalenceCiències de la salutWaist-to-height ratioNutrition and DieteticsConfoundingMiddle AgedCiencias de la saludurinePolifenolsObesitatFemalemedicine.symptomWaist CircumferencePREDIMEDmedicine.medical_specialtyWaistArticle03 medical and health sciencesInternal medicinemedicineHumansoverweightObesityAged030109 nutrition & dieteticsWaist-Height Ratiobusiness.industryBody WeightHealth sciencesPolyphenolsNUTRICIÓoverweight; obesity; polyphenol; urine; PREDIMEDDIETOTERÀPIA2072-6643medicine.diseaseObesitySurgerypolyphenolCross-Sectional StudiesNutrition AssessmentbusinessBody mass indexBiomarkersFood ScienceFollow-Up StudiesNutrients
researchProduct

Determinants of the Quality of Warfarin Control after Venous Thromboembolism and Validation of the SAMe-TT2-R2 Score: An Analysis of Hokusai-VTE.

2019

Background Time in therapeutic range (TTR) measures the quality of vitamin K antagonist (VKA) anticoagulation. In patients with atrial fibrillation, the dichotomized SAMe-TT2-R2 score (≥2 vs. < 2 points) can predict if adequate TTR is unlikely to be achieved. Aims We validated the SAMe-TT2-R2 score in patients with venous thromboembolism (VTE) randomized to the warfarin arm of the Hokusai-VTE trial. Patients and Methods A total of 3,874 patients were included in the primary analysis (day 31–180 from randomization). The efficacy and safety outcomes were symptomatic recurrent VTE and major or clinically relevant non-major bleeding. Results The rates of recurrent VTE and bleeding events we…

0301 basic medicineMalevitamin K antagonistEXTERNAL VALIDATIONTime FactorsVitamin KWarfarin/therapeutic use030204 cardiovascular system & hematologyTHERAPYSeverity of Illness Indexlaw.inventionchemistry.chemical_compound0302 clinical medicineRandomized controlled trialEdoxabanlawRecurrenceAtrial FibrillationVitamin K/antagonists & inhibitorsStrokeRISKAtrial fibrillationHematologyVenous ThromboembolismVitamin K antagonistMiddle Agedrisk assessment modelTIMEPREDICTSTreatment OutcomeAnticoagulants/therapeutic useResearch DesignANTICOAGULATION CONTROLFemaleLife Sciences & Biomedicinemedicine.drugHemorrhage/drug therapyAdultmedicine.medical_specialtyRandomizationmedicine.drug_classvenous thromboembolismHemorrhageRisk AssessmentSensitivity and SpecificityEDOXABAN03 medical and health sciencesDouble-Blind MethodVITAMIN-K ANTAGONISTSInternal medicinemedicineNONVALVULAR ATRIAL-FIBRILLATIONORAL ANTICOAGULANTHumansInternational Normalized RatioBlood CoagulationScience & Technologybusiness.industryquality of treatmentWarfarinAnticoagulantsmedicine.diseasewarfarinClinical trial030104 developmental biologyPeripheral Vascular DiseasechemistryBlood Coagulation/drug effectsAtrial Fibrillation/bloodCardiovascular System & CardiologyLinear ModelsWarfarinbusinessVenous Thromboembolism/drug therapyThrombosis and haemostasis
researchProduct